Skip to content

Jasper Therapeutics, Inc.

Public company
Headquarters
REDWOOD CITY, California
Industry
Biotechnology
Ticker
JSPR
CIK
0001788028

WARN notices since 2024

0
None on record

Workers affected since 2024

0
Across 0 notices

Executive changes, last 12 months

4
3 appointments, 1 departure

Last event

Sep 28, 2026
Executive departureCFO departs: Herb Cross

Workers affected over time

Cumulative workers in WARN notices since 2024

Not enough notices to chart yet.

Leadership

Role and personSinceChange
CFOHerb CrossSep 28, 2026Departed
interim Principal Financial OfficerJeet MahalSep 28, 2026Appointed
interim Principal Accounting OfficerRick RuizSep 28, 2026Appointed
interim Corporate SecretaryMatthew RosSep 28, 2026Appointed

Related companies

Same industry and state, with recent events.

  1. Executive departure

    CFO departs: Herb Cross

    Herb Cross, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc., resigns the role, effective October 9, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary

    Source: SEC 8-K, filed Sep 28, 2026

  2. Executive appointment

    interim Principal Financial Officer appointed: Jeet Mahal

    Jeet Mahal was named interim Principal Financial Officer of Jasper Therapeutics, Inc., effective October 9, 2026. Jeet Mahal succeeds Herb Cross. The company reported the change in an 8-K that cites Item 5.02.

    Role: interim Principal Financial Officer

    Source: SEC 8-K, filed Sep 28, 2026

  3. Executive appointment

    interim Principal Accounting Officer appointed: Rick Ruiz

    Rick Ruiz was named interim Principal Accounting Officer of Jasper Therapeutics, Inc., effective October 9, 2026. Rick Ruiz succeeds Herb Cross. The company reported the change in an 8-K that cites Item 5.02.

    Role: interim Principal Accounting Officer

    Source: SEC 8-K, filed Sep 28, 2026

  4. Executive appointment

    interim Corporate Secretary appointed: Matthew Ros

    Matthew Ros was named interim Corporate Secretary of Jasper Therapeutics, Inc., effective October 9, 2026. Matthew Ros succeeds Herb Cross. The company reported the change in an 8-K that cites Item 5.02.

    Role: interim Corporate Secretary

    Source: SEC 8-K, filed Sep 28, 2026

Last verified Nov 8, 2026